Addenbrooke's Hospital, Department of Vascular Surgery
Cambridge, CB2 0QQ, United Kingdom
NCT Number: NCT03294902
The Pedra Technologies' PedraTM device is a non-invasive, diagnostic device intended to measure foot perfusion by assessing blood flow. The PedraTM device comprises a compact instrument console connected to a sensor that is pasted onto the patient's foot during perfusion assessment. Through skin contact, the device is able to monitor tissue perfusion at depths of up to 7.5mm. The monitor console contains opto-electronic instrumentation including coherent infrared light sources, photo detectors, and display/control electronics. The sensor comprises passive fiber-optic conduits, which transfer infrared light from the console to the patient, and relays scattered light from the patient back to the console. The intensity of light emitted from the sensor is less than 3 mW, well within the safety envelope of Class I laser systems and comparable (or lower than) other commercially available devices such as laser Doppler systems. The sole point of contact with the patient is a layer of medical grade adhesive tape, which is used to paste the flat sensor onto intact skin.
Looking for future studies?
Notify Me40 year–90 year
All sexes
Observational
Cambridge, CB2 0QQ, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
General Inclusion Criteria:
Cohort Specific Inclusion Criteria:
Critical Limb Ischaemia Group Inclusion Criteria:
Peripheral Arterial Disease Group Inclusion Criteria:
PAD-Free Group Inclusion Criteria:
Exclusion criteria
This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
Time frame: Baseline visit: 30-60 minutes after pad removal
This observation assessment is completed by the physician post removal of the adhesive pads. It is either a "yes" or a "no" in observing if there is a skin reaction to the adhesive pads when they are removed from the skin and also documentation of what type of reaction (rash; local oedema, blistering of the skin).
Time frame: During procedure visit: 30-60 minutes after pad removal
This observation assessment is completed by the physician post removal of the adhesive pads. It is either a "yes" or a "no" in observing if there is a skin reaction to the adhesive pads when they are removed from the skin and also documentation of what type of reaction (rash; local oedema, blistering of the skin).
Time frame: 36-hrs post-procedure/ discharge visit: 30-60 minutes after pad removal
This observation assessment is completed by the physician post removal of the adhesive pads. It is either a "yes" or a "no" in observing if there is a skin reaction to the adhesive pads when they are removed from the skin and also documentation of what type of reaction (rash; local oedema, blistering of the skin).
Pedra Technology, PTE LTD
Industry
Acronym: IROAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06416644
Arterial Occlusive Diseases, Arteriosclerosis
Faro, Algarve, Portugal
View Trial DetailsNCT05858905
Arterial Occlusive Diseases, Arteriosclerosis
Palo Alto, California, United States
View Trial DetailsNCT05009862
Arterial Occlusive Diseases, Arteriosclerosis
Nashville, Tennessee, United States
View Trial DetailsNCT04130737
Arterial Occlusive Diseases, Arteriosclerosis
Mesa, Arizona, United States
View Trial Details